ストックスクリーナーアプリを入手
256.76
8.73%
-23.36
アフターアワーズ：
280.12
23.36
+9.10%
前日終値:
$280.12
開ける：
$261.69
24時間の取引高:
939.88K
Relative Volume:
3.02
時価総額：
$6.93B
収益：
$2.58B
当期純損益:
$759.90M
株価収益率:
9.1973
EPS:
27.9168
ネットキャッシュフロー:
$374.60M
1週間 パフォーマンス:
-11.18%
1か月 パフォーマンス:
-8.15%
6か月 パフォーマンス:
-19.99%
1年 パフォーマンス:
+6.34%
1日の値動き範囲:
$242.28
$264.22
1週間の範囲:
$242.28
$294.05
52週間の値動き範囲:
$211.43
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
名前
Bio Rad Laboratories Inc
セクター
電話
(510) 724-7000
住所
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
256.76 | 7.54B | 2.58B | 759.90M | 374.60M | 27.92 |
ABT
Abbott Laboratories
|
89.47 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
294.69 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.00 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.51 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.99 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-06-16 | 開始されました | Wells Fargo | Overweight |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-01-28 | 繰り返されました | Citigroup | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2018-10-17 | 開始されました | Goldman | Buy |
| 2018-09-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-02-16 | ダウングレード | CL King | Buy → Neutral |
| 2017-07-13 | 開始されました | Wells Fargo | Outperform |
| 2017-06-28 | アップグレード | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Hold |
| 2016-10-13 | 開始されました | CL King | Buy |
| 2015-05-06 | 繰り返されました | Jefferies | Buy |
| 2009-12-18 | 開始されました | Maxim Group | Buy |
| 2009-11-06 | 開始されました | Jefferies & Co | Buy |
| 2009-07-17 | 開始されました | Soleil | Buy |
| 2007-09-26 | 開始されました | Banc of America Sec | Buy |
| 2007-02-23 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Bio Rad Laboratories Inc (BIO) 最新ニュース
Bio-Rad Laboratories stock falls on lowered revenue outlook By Investing.com - Investing.com Canada
Bio-Rad drops 10.2% as guidance cut and Sartorius valuation hit overshadow Q1 results - Quiver Quantitative
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU - Benzinga
Why Bio-Rad Laboratories Is Plunging 10.8%: Wells Fargo Maintains Equal-Weight - AlphaStreet
Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings - MarketBeat
Bio-Rad Laboratories, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption - MSN
Bio-Rad Laboratories Q1 2026 Earnings Call Transcript - MarketBeat
Bio-Rad Laboratories Inc (BIO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Bio-Rad Laboratories Q1 Earnings Call Highlights - MarketBeat
BIO SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Bio-Rad Reports First-Quarter 2026 Financial Results - BioSpace
Bio-Rad Q1 2026 slides: earnings beat masks currency headwinds By Investing.com - Investing.com Canada
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results - MarketBeat
Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus
MSN Money - MSN
Bio-Rad (BIO) Reports Strong Q1 Revenue Amidst Market Challenges - GuruFocus
Bio-Rad Q1 2026 slides: earnings beat masks currency headwinds - Investing.com
Bio-Rad Laboratories (BIO) Lags Q1 Earnings Estimates - Yahoo Finance
Earnings call transcript: Bio-Rad Q1 2026 beats expectations, stock climbs - Investing.com UK
Bio-Rad Laboratories Reports Q1 2026 Results, Cuts Outlook - TipRanks
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - Benzinga
Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results - MarketBeat
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss - Quiver Quantitative
Bio-Rad Laboratories Q1 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Bio-Rad: Q1 Earnings Snapshot - KTVB
Q1 2026 Bio Rad Laboratories Inc Earnings Call Transcript - GuruFocus
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q1 Revenue $592.1M, vs. FactSet Est of $589.9M - marketscreener.com
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Huge Sartorius loss drives Bio-Rad (NYSE: BIO) Q1 2026 net loss - Stock Titan
Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance - Stock Titan
Bio-Rad earnings on deck: Can margin recovery offset academic headwinds? - Investing.com Australia
Bio-Rad earnings on deck: Can margins recover after rough 2025? - Investing.com Canada
Food Diagnostics Market to Reach USD 32.8 Billion by 2033 at 9.0% - openPR.com
Transcriptomics Technologies Market to Reach USD 20.64 Billion - openPR.com
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers - News-Medical
Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding - Stock Titan
Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes - Stock Titan
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report - GlobeNewswire
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report 2025-2034 Featuring Roche, Danaher, Abbott Laboratories, Thermo Fischer Scientific, Bio-Rad Laboratories, Sysmex, BD & Co, and Biomerieux - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential - DirectorsTalk Interviews
Citigroup downgrades Bio-Rad Laboratories (BIO) - MSN
Bio-Rad Laboratories, Inc. Amends 2017 Incentive Award Plan and Updates Entity Information in April 2026 8-K Filing - Minichart
Bio-Rad Laboratories (BIO.US) will release its earnings report after the market closes on April 30. - Moomoo
Bio-Rad Laboratories Stockholders Approve Directors and Governance Items - TipRanks
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns - Yahoo Finance
Bio-Rad Laboratories Inc (BIO) Shares Fall 6.4% -- What GF Score of 77 Tells Investors - GuruFocus
Greg K. Hinckley adds Bio-Rad (BIO) shares through RSU vesting and grant - Stock Titan
Bio Rad Laboratories Inc (BIO) 財務データ
収益
当期純利益
現金流量
EPS
Bio Rad Laboratories Inc (BIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Apr 24 '26 |
Option Exercise |
0.00 |
186 |
0 |
827 |
| Hinckley Greg K | Director |
Apr 21 '26 |
Option Exercise |
0.00 |
407 |
0 |
1,215 |
| PEI MELINDA LITHERLAND | Director |
Apr 21 '26 |
Option Exercise |
0.00 |
407 |
0 |
715 |
| EDWARDS JEFFREY L | Director |
Apr 21 '26 |
Option Exercise |
0.00 |
407 |
0 |
715 |
| PINKSTON ARNOLD A | Director |
Apr 21 '26 |
Option Exercise |
0.00 |
407 |
0 |
715 |
0.57%
0.86%
大文字化:
|
ボリューム (24 時間):